Ionis Pharmaceuticals Inc (IONS)vsRoyalty Pharma Plc (RPRX)
IONS
Ionis Pharmaceuticals Inc
$74.48
-0.87%
HEALTHCARE · Cap: $12.11B
RPRX
Royalty Pharma Plc
$55.02
-0.76%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 131% more annual revenue ($2.44B vs $1.06B). RPRX leads profitability with a 33.9% profit margin vs -30.9%. RPRX appears more attractively valued with a PEG of 2.05. RPRX earns a higher WallStSmart Score of 65/100 (C+).
IONS
Avoid31
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+49.1%
Fair Value
$165.82
Current Price
$74.48
$91.34 discount
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 87.0% year-over-year
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Trading at 25.2x book value
ROE of -66.5% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IONS
The strongest argument for IONS centers on Revenue Growth. Revenue growth of 87.0% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : IONS
The primary concerns for IONS are Piotroski F-Score, PEG Ratio, Price/Book. Debt-to-equity of 4.15 is elevated, increasing financial risk.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
IONS profiles as a hypergrowth stock while RPRX is a mature play — different risk/reward profiles.
RPRX carries more volatility with a beta of 0.42 — expect wider price swings.
IONS is growing revenue faster at 87.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 31/100), backed by strong 33.9% margins and 11.0% revenue growth. IONS offers better value entry with a 49.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ionis Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?